Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848300 | 0.89 | POLB (0.54) | KDM4EALDH1A1GAAPOLBMAPK1 | |
| SCHEMBL4848123 | 0.88 | NCF1 (0.50) | KDM4EALDH1A1GAAPOLBNCF1 | |
| SCHEMBL11762958 | 0.86 | PDE5A (0.49) | KDM4EALDH1A1GAAPOLBNCF1 | |
| SCHEMBL5943486 | 0.85 | NCF1 (0.59) | KDM4EALDH1A1GAAPOLBNCF1 | |
| SCHEMBL11754025 | 0.84 | BCHE (0.47) | KDM4EALDH1A1GAAPOLBMAPK1 | |
| SCHEMBL9850350 | 0.83 | NCF1 (0.57) | KDM4EALDH1A1GAAPOLBNCF1 | |
| SCHEMBL13365646 | 0.82 | KDM4E (0.61) | KDM4EALDH1A1GAAPOLBMAPK1 | |
| SCHEMBL7511217 | 0.81 | NCF1 (0.60) | KDM4ENCF1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5943525 | 0.81 | NCF1 (0.55) | KDM4EALDH1A1GAANCF1RAB9A | |
| Hydrochloric Acid SCHEMBL15286478 | 0.80 | NCF1 (0.53) | KDM4EALDH1A1GAANCF1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969577-B2 | Curable composition comprising a thermolatent base | BASF SE (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969577-B2 | Curable composition comprising a thermolatent base | BASF SE (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969577-B2 | Curable composition comprising a thermolatent base | BASF SE (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2367794-B1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2013-01-09 | — | — | EP | disclosed |
| EP-2367794-B1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2367794-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010057922-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010057922-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2010-05-27 | — | — | WO | disclosed |
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| WO-1998045283-A1 | MICROBICIDAL BENZOTHIOPHENE S-OXIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-15 | — | — | WO | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
| US-4348398-A | Quinolinyl ethanolamines | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1982-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | KDM4E 4333/4885ALDH1A1 745/4885GAA 3605/4885 |
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | COIL, MAPT, ASH2L | KDM4E 1082/4885ALDH1A1 2185/4885GAA 2430/4885 |
| US-20090215815-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | KDM4E 2061/4885ALDH1A1 1561/4885GAA 2404/4885 |
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | KDM4E 2031/4885ALDH1A1 1866/4885GAA 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.